{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:05:31Z","timestamp":1782853531044,"version":"3.54.5"},"reference-count":95,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The management of peritoneal metastases from gastric cancer origin has evolved considerably over the last three decades with the establishment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as efficacious therapies in carefully selected patients. Other approaches such as the use of prophylactic\/adjuvant HIPEC in patients who are considered high-risk and those with positive peritoneal cytology will benefit from additional data before being adopted into routine clinical practice. Lastly, there are new and emerging intraperitoneal chemotherapy techniques such as early post-operative intraperitoneal chemotherapy (EPIC) for residual microscopic disease, and pressurized intraperitoneal aerosolized chemotherapy (PIPAC) for patients with advanced unresectable peritoneal carcinomatosis, which are currently under evaluation in clinical trials. The following review outlines the natural history of gastric cancer, currently available neoadjuvant and adjuvant therapies for resectable disease, and existing evidence supporting various approaches to CRS and intraperitoneal chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers11111662","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T04:44:31Z","timestamp":1572237871000},"page":"1662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer"],"prefix":"10.3390","volume":"11","author":[{"given":"Adriana C.","family":"Gamboa","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, 1365B Clifton Road NE, Suite B4000, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua H.","family":"Winer","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, 1365B Clifton Road NE, Suite B4000, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"6868","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2014An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark Prev."},{"key":"ref_3","unstructured":"(2019, October 10). SEER Cancer Stat Facts: Stomach Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","article-title":"The Value of Peritoneal Cytology as a Preoperative Predictor in Patients with Gastric Carcinoma Undergoing a Curative Resection","volume":"12","author":"Bentrem","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","first-page":"2131","article-title":"Relationship between Area of Serosal Invasion and Intraperitoneal Free Cancer Cells in Patients with Gastric Cancer","volume":"14","author":"Ikeguchi","year":"1994","journal-title":"Anticancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful Intraperitoneal Hyperthermic Chemoperfusion for the Prevention of Postoperative Peritoneal Recurrence in Patients with Advanced Gastric Carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00268-002-6279-7","article-title":"Incidence and Factors Associated with Recurrence Patterns after Intended Curative Surgery for Gastric Cancer","volume":"27","author":"Wu","year":"2003","journal-title":"World J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Glehen, O., Passot, G., Villeneuve, L., Vaudoyer, D., Bin-Dorel, S., Boschetti, G., Piaton, E., and Garofalo, A. (2014). GASTRICHIP: D2 Resection and Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Carcinoma: A Randomized and Multicenter Phase III Study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-183"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/bjs.1800830526","article-title":"Prognostic Value of Positive Cytology Findings from Abdominal Washings in Patients with Gastric Cancer","volume":"83","author":"Bonenkamp","year":"1996","journal-title":"Br. J. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/bjs.1800770425","article-title":"Prognostic Significance of Serosal Invasion and Free Intraperitoneal Cancer Cells in Gastric Cancer","volume":"77","author":"Boku","year":"1990","journal-title":"Br. J. Surg."},{"key":"ref_12","first-page":"148420","article-title":"Effects of Neoadjuvant Intraperitoneal\/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer","volume":"2012","author":"Yonemura","year":"2012","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07357907.2012.654871","article-title":"Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC\u2014Overview and Basics","volume":"30","author":"Brucher","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13193-011-0074-6","article-title":"Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients","volume":"2","author":"Mezhir","year":"2011","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","article-title":"Evaluation and Treatment of Malignant Ascites Secondary to Gastric Cancer","volume":"21","author":"Maeda","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_16","unstructured":"(2019, October 18). National Comprehensive Cancer Network (NCCN). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/0360-3016(90)90344-J","article-title":"Patterns of Failure Following Curative Resection of Gastric Carcinoma","volume":"19","author":"Landry","year":"1990","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.hoc.2017.01.004","article-title":"Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?","volume":"31","author":"Lorenzen","year":"2017","journal-title":"Hematol.\/Oncol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2\/3 Trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_21","first-page":"Cd008107","article-title":"Perioperative Chemo(Radio)Therapy Versus Primary Surgery for Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction, and Lower Esophagus","volume":"5","author":"Ronellenfitsch","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000350877","article-title":"Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East","volume":"30","author":"Fujitani","year":"2013","journal-title":"Dig. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association (2017). Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer, 20, 1\u201319.","DOI":"10.1007\/s10120-016-0622-4"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-014-0388-5","article-title":"A Systematic Review and Meta-Analysis of Gastric Cancer Treatment in Patients with Positive Peritoneal Cytology","volume":"18","author":"Cabalag","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant Capecitabine plus Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): 5-year Follow-Up of an Open-Label, Randomised Phase 3 Trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis","volume":"303","author":"Paoletti","year":"2010","journal-title":"Jama"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdm128","article-title":"Adjuvant Chemotherapy with Epirubicin, Leucovorin, 5-fluorouracil and Etoposide Regimen in Resected Gastric Cancer Patients: A Randomized Phase III Trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)","volume":"18","author":"Giuliani","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jnci\/djk131","article-title":"Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial","volume":"99","author":"Cascinu","year":"2007","journal-title":"J. Nat. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdj077","article-title":"Randomized Phase III Trials of Adjuvant FAMTX or FEMTX Compared with Surgery Alone in Resected Gastric Cancer. A Combined Analysis of the EORTC GI Group and the ICCG","volume":"17","author":"Nitti","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7343","DOI":"10.3748\/wjg.v21.i24.7343","article-title":"Perioperative Chemotherapy for Resectable Gastric Cancer: MAGIC and Beyond","volume":"21","author":"Choi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with D2 Lymph Node Dissection: The ARTIST Trial","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dikken, J.L., van Sandick, J.W., Maurits Swellengrebel, H.A., Lind, P.A., Putter, H., Jansen, E.P., Boot, H., van Grieken, N.C., van de Velde, C.J., and Verheij, M. (2011). Neo-Adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy for Patients with Resectable Gastric Cancer (CRITICS). BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-329"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2009.06.003","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Overview and Rationale","volume":"33","author":"Shen","year":"2009","journal-title":"Curr. Probl. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1989.7.9.1310","article-title":"Phase II Study with the Combination Etoposide, Doxorubicin, and Cisplatin in Advanced Measurable Gastric Cancer","volume":"7","author":"Preusser","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L","article-title":"Resectable Gastric Carcinoma. An Evaluation of Preoperative and Postoperative Chemotherapy","volume":"68","author":"Ajani","year":"1991","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal Carcinomatosis of Gastric Origin: A Population-Based Study on Incidence, Survival and Risk Factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_41","first-page":"253","article-title":"Hyperthermic Peritoneal Perfusion System in Canines","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy Procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.20517\/2394-4722.2017.67","article-title":"Gastric Cancer: Prevention and Treatment of Peritoneal Metastases","volume":"4","author":"Sugarbaker","year":"2018","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","article-title":"A Pharmacological Review on Intraperitoneal Chemotherapy for Peritoneal Malignancy","volume":"2","author":"Yan","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E","article-title":"Pharmacokinetics of Intraperitoneal Oxaliplatin: Experimental Studies","volume":"76","author":"Pestieau","year":"2001","journal-title":"J. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical Research Methodologies in Diagnosis and Staging of Patients with Peritoneal Carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U","article-title":"Prophylactic Therapy for Peritoneal Recurrence of Gastric Cancer by Continuous Hyperthermic Peritoneal Perfusion with Mitomycin C","volume":"61","author":"Koga","year":"1988","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of Peritoneal Dissemination from Gastric Cancer by Peritonectomy and Chemohyperthermic Peritoneal Perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br. J. Surg."},{"key":"ref_49","first-page":"809","article-title":"Subtotal Peritonectomy with Chemohyperthermic Peritoneal Perfusion for Peritonitis Carcinomatosa in Gastrointestinal Cancer","volume":"7","author":"Fujimura","year":"2000","journal-title":"Oncol. Rep."},{"key":"ref_50","first-page":"1776","article-title":"Intraoperative Chemohyperthermic Peritoneal Perfusion as An Adjuvant to Gastric Cancer: Final Results of A Randomized Controlled Study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepato-Gastroenterology"},{"key":"ref_51","first-page":"45","article-title":"Chemotherapy for Intraperitoneal Use: A Review of Hyperthermic Intraperitoneal Chemotherapy and Early Post-Operative Intraperitoneal Chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/1097-0142(19930901)72:5<1631::AID-CNCR2820720523>3.0.CO;2-I","article-title":"Evaluation of Computed Tomography in Patients with Peritoneal Carcinomatosis","volume":"72","author":"Jacquet","year":"1993","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","article-title":"Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy","volume":"26","author":"Newhook","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant Treatment of Gastric Cancer with Peritoneal Dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","article-title":"Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan","volume":"21","author":"Canbay","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s101200100013","article-title":"A Controlled Clinical Study of Serosa-Invasive Gastric Carcinoma Patients who Underwent Surgery Plus Intraperitoneal Hyperthermo-Chemo-Perfusion (IHCP)","volume":"4","author":"Kim","year":"2001","journal-title":"Gastric Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","article-title":"A Systematic Review and Meta-Analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer","volume":"14","author":"Yan","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal Chemotherapy in Advanced Gastric Cancer. Meta-Analysis of Randomized Trials","volume":"40","author":"Coccolini","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year Experience-A Meta-Analysis of Randomised and High-Quality Non-Randomised Studies of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q","article-title":"Intraperitoneal Thermochemotherapy for Prevention of Peritoneal Recurrence of Gastric Cancer. Final Results of a Randomized Controlled Study","volume":"73","author":"Hamazoe","year":"1994","journal-title":"Cancer"},{"key":"ref_62","first-page":"581","article-title":"Effects of Continuous Hyperthermic Peritoneal Perfusion on Prognosis of Gastric Cancer with Serosal Invasion","volume":"161","author":"Ikeguchi","year":"1995","journal-title":"Eur. J. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000012016","article-title":"Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis","volume":"57","author":"Hirose","year":"1999","journal-title":"Oncology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000093778","article-title":"Efficacy and Safety of Intraoperative Peritoneal Hyperthermic Chemotherapy for Advanced Gastric Cancer Patients with Serosal Invasion. A Long-Term Follow-Up Study","volume":"23","author":"Zhu","year":"2006","journal-title":"Dig. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00000658-199011000-00005","article-title":"Positive Results of Combined Therapy of Surgery and Intraperitoneal Hyperthermic Perfusion for Far-Advanced Gastric Cancer","volume":"212","author":"Fujimoto","year":"1990","journal-title":"Ann. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF01675656","article-title":"Hyperthermo-Chemotherapy Combined with Cytoreductive Surgery for the Treatment of Gastric Cancer with Peritoneal Dissemination","volume":"15","author":"Yonemura","year":"1991","journal-title":"World J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0039-6060(96)80145-0","article-title":"Effects of Intraoperative Chemohyperthermia in Patients with Gastric Cancer with Peritoneal Dissemination","volume":"119","author":"Yonemura","year":"1996","journal-title":"Surgery"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","article-title":"Improved Mortality Rate of Gastric Carcinoma Patients with Peritoneal Carcinomatosis Treated with Intraperitoneal Hyperthermic Chemoperfusion Combined with Surgery","volume":"79","author":"Fujimoto","year":"1997","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archsurg.139.1.20","article-title":"Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising from Gastric Cancer","volume":"139","author":"Glehen","year":"2004","journal-title":"Arch. Surg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jso.21519","article-title":"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy to Treat Gastric Cancer with Ascites and\/or Peritoneal Carcinomatosis: Results from a Chinese Center","volume":"101","author":"Yang","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1245\/s10434-013-3327-5","article-title":"Aggressive Locoregional Surgical Therapy for Gastric Peritoneal Carcinomatosis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2018.36.4_suppl.8","article-title":"CYTO-CHIP: Cytoreductive Surgery Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastasis: A Propensity-Score Analysis from BIG RENAPE and FREGAT Working Groups","volume":"36","author":"Bonnot","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02468883","article-title":"The General Rules for the Gastric Cancer Study in Surgery and Pathology. Part I. Clinical Classification","volume":"11","author":"Kajitani","year":"1981","journal-title":"Jpn. J. Surg."},{"key":"ref_75","first-page":"5790","article-title":"Early Postoperative Intraperitoneal Chemotherapy as an Adjuvant Therapy to Surgery for Peritoneal Carcinomatosis from Gastrointestinal Cancer: Pharmacological Studies","volume":"50","author":"Sugarbaker","year":"1990","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-001-0067-7","article-title":"Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial","volume":"25","author":"Yu","year":"2001","journal-title":"World J. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4143\/crt.2014.46.3.270","article-title":"Early Postoperative Intraperitoneal Chemotherapy for Macroscopically Serosa-Invading Gastric Cancer Patients","volume":"46","author":"Kwon","year":"2014","journal-title":"Cancer Res. Treat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1245\/s10434-009-0774-0","article-title":"Malignant Ascites Symptom Cluster in Patients Referred for Paracentesis","volume":"17","author":"Husain","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00000658-198606000-00009","article-title":"Malignant Ascites. Clinical and Experimental Observations","volume":"203","author":"Garrison","year":"1986","journal-title":"Ann. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant Ascites: A Review of Prognostic Factors, Pathophysiology and Therapeutic Measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal Hyperthermic Perfusion Combined with Surgery Effective for Gastric Cancer Patients with Peritoneal Seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","article-title":"Laparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature","volume":"19","author":"Facchiano","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","article-title":"Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites","volume":"21","author":"Randle","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Katdare, N., Probhu, R., and Bhatt, A. (2018). Locoregional and Palliative Therapies for Patients with Unresectable Peritoneal Metastases. Manage. Perit. Metastases-Cytoreductive Surg. Hipec Beyond, 527\u2013559.","DOI":"10.1007\/978-981-10-7053-2_22"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a Novel Approach for Intraperitoneal Drug Delivery and the Related Device","volume":"26","author":"Hetzel","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High Intra-Abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.nantod.2009.08.008","article-title":"Self-Assembled and Nanostructured Hydrogels for Drug Delivery and Tissue Engineering","volume":"4","author":"Chung","year":"2009","journal-title":"Nano Today"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 Secreting Tumor-Targeted Chimeric Antigen Receptor T Cells Eradicate Ovarian Tumors in Vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The Use of Bevacizumab to Palliate Symptomatic Ascites in Patients with Refractory Ovarian Carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open-Label Safety and Efficacy Pilot Trial of Intraperitoneal Bevacizumab as Palliative Treatment in Refractory Malignant Ascites","volume":"25","author":"Elsaid","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000324667","article-title":"Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I\/II Trial","volume":"34","author":"Strohlein","year":"2011","journal-title":"Onkologie"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The Trifunctional Antibody Catumaxomab for the Treatment of Malignant Ascites due to Epithelial Cancer: Results of a Prospective Randomized Phase II\/III Trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(19900401)65:7<1495::AID-CNCR2820650708>3.0.CO;2-1","article-title":"Histologic Changes Induced by Intraperitoneal Chemotherapy with 5-fluorouracil and Mitomycin C in Patients with Peritoneal Carcinomatosis from Cystadenocarcinoma of the Colon or Appendix","volume":"65","author":"Sugarbaker","year":"1990","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER Phase III Trial of Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:38Z","timestamp":1760189378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["cancers11111662"],"URL":"https:\/\/doi.org\/10.3390\/cancers11111662","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,26]]}}}